Esmo 2022 movers – Kras backfires
Inhibition of Kras dominated Esmo, though probably not in the way some had hoped.
Padcev has the front line in its sights
But the main question for deal-hungry investors will be what this means for the chances of Merck & Co buying out Seagen.
Are we there yet?
Second-quarter share price movements give another glimpse of the dire state of the markets, but there might be reasons for optimism.
The trigger for a Seagen buyout
Seagen is vulnerable to takeover, but whether a deal happens – and at what price – depends on at least one catalyst.
